Barcode Nanotech
Ronen Eavri possesses extensive experience in the biopharmaceutical and healthcare sectors. Currently a member of 8400 - The Health Network since January 2020 and serving as CEO and Co-founder of Barcode Nanotech since February 2017, Ronen previously held leading scientific roles at Johnson & Johnson from 2012 to 2017, focusing on preclinical development, product formulation, and patent applications. Prior roles include work as a scientist at D Pharm LTD., conducting research on innovative biopharmaceuticals, and a postdoctoral fellowship at the Massachusetts Institute of Technology, studying mechanisms of learning and memory in the mouse brain. Academic credentials include an MBA from Technion - Israel Institute of Technology and multiple degrees in Biotechnology and Biochemistry from The Hebrew University of Jerusalem.
This person is not in any teams
This person is not in any offices
Barcode Nanotech
Barcode designs a proprietary technology designed for use for personalized cancer drug screening. Its proprietary technology quickly and reliably assesses the efficacy of different cancer drugs directly on the tumor within the patient's own body, enabling physicians to access a new tool that matches each patient with the optimally potentmedicine, during the different stages of the disease to improve cancer care.